{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:09:21Z","timestamp":1791407361692,"version":"4.3.3"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007150","name":"United Therapeutics Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1378\/chest.11-2212","type":"journal-article","created":{"date-parts":[[2012,5,25]],"date-time":"2012-05-25T20:18:57Z","timestamp":1337977137000},"page":"1383-1390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":295,"title":["Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and\/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study)"],"prefix":"10.1016","volume":"142","author":[{"given":"Victor F.","family":"Tapson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Kermeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Keogh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roblee P.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Frantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Badesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adaani E.","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley M.","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Laliberte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Sigman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Arneson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazzareno","family":"Gali\u00e8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1378\/chest.11-2212_bib1","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","volume":"53","author":"McLaughlin","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"10.1378\/chest.11-2212_bib2","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","article-title":"Treatment of pulmonary arterial hypertension","volume":"351","author":"Humbert","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1378\/chest.11-2212_bib3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1378\/chest.11-2212_bib4","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1378\/chest.11-2212_bib5","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1378\/chest.129.3.683","article-title":"Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial","volume":"129","author":"Tapson","year":"2006","journal-title":"Chest"},{"issue":"18","key":"10.1378\/chest.11-2212_bib6","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1378\/chest.11-2212_bib7","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1378\/chest.11-2212_bib8","first-page":"2894","article-title":"Tadalafil therapy for pulmonary arterial hypertension [published correction appears in Circulation. 2011;124(10):e279. Dosage error in article text.]","volume":"119","author":"Gali\u00e8","year":"2009","journal-title":"Circulation"},{"issue":"20","key":"10.1378\/chest.11-2212_bib9","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Gali\u00e8","year":"2005","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1378\/chest.11-2212_bib10","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Gali\u00e8","year":"2008","journal-title":"Circulation"},{"issue":"12","key":"10.1378\/chest.11-2212_bib11","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1378\/chest.11-2212_bib12","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0735-1097(02)01786-2","article-title":"Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial","volume":"39","author":"Gali\u00e8","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1378\/chest.11-2212_bib13","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/s10096-003-1024-1","article-title":"Micrococcus infection in patients receiving epoprostenol by continuous infusion","volume":"22","author":"Yap","year":"2003","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"10.1378\/chest.11-2212_bib14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1378\/chest.126.1.90","article-title":"Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension","volume":"126","author":"Oudiz","year":"2004","journal-title":"Chest"},{"key":"10.1378\/chest.11-2212_bib15","unstructured":"Remodulin [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2010."},{"key":"10.1378\/chest.11-2212_bib16","unstructured":"Flolan (epoprostenol sodium) for injection [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2011."},{"issue":"3","key":"10.1378\/chest.11-2212_bib17","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1378\/chest.06-2118","article-title":"Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial","volume":"132","author":"Rubenfire","year":"2007","journal-title":"Chest"},{"issue":"12","key":"10.1378\/chest.11-2212_bib18","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1164\/rccm.200505-766OC","article-title":"Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension","volume":"172","author":"Gomberg-Maitland","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1378\/chest.11-2212_bib19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.healun.2009.09.005","article-title":"Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial","volume":"29","author":"Hiremath","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1378\/chest.11-2212_bib20","doi-asserted-by":"crossref","unstructured":"White RJ, Allen R, Torres F, et al. Sustained plasma concentrations of treprostinil following chronic dosing of oral treprostinil in patients with pulmonary arterial hypertension. Poster presented at: American Thoracic Society International Conference; May 15-20, 2009; San Deigo, CA.","DOI":"10.1164\/ajrccm-conference.2009.179.1_MeetingAbstracts.A3360"},{"issue":"1","key":"10.1378\/chest.11-2212_bib21","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/0091270003261343","article-title":"Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion","volume":"44","author":"Wade","year":"2004","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"10.1378\/chest.11-2212_bib22","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1177\/0091270009351173","article-title":"Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers","volume":"50","author":"Gotzkowsky","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1378\/chest.11-2212_bib23","doi-asserted-by":"crossref","unstructured":"Rollins K, Peterson L, Laliberte K, Gotzkowsky SK, Wade M, Mottola D. Overview of the drug-drug interaction potential with treprostinil. Poster presented at: American Thoracic Society International Conference; May 15-20, 2009; San Deigo, CA.","DOI":"10.1164\/ajrccm-conference.2009.179.1_MeetingAbstracts.A3367"},{"issue":"1","key":"10.1378\/chest.11-2212_bib24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/0002-9149(89)90652-8","article-title":"Changes in dyspnea-fatigue ratings as indicators of quality of life in the treatment of congestive heart failure","volume":"64","author":"Feinstein","year":"1989","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1378\/chest.11-2212_bib25","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1183\/09031936.06.00057906","article-title":"Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension","volume":"28","author":"Hoeper","year":"2006","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1378\/chest.11-2212_bib26","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1378\/chest.11-2212_bib27","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial","volume":"149","author":"Simonneau","year":"2008","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1378\/chest.11-2212_bib28","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/0003-4819-136-7-200204020-00008","article-title":"Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension","volume":"136","author":"Ghofrani","year":"2002","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1378\/chest.11-2212_bib29","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"issue":"5","key":"10.1378\/chest.11-2212_bib30","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/eurheartj\/ehi728","article-title":"Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension","volume":"27","author":"Provencher","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1378\/chest.11-2212_bib31","first-page":"A1043","article-title":"Treatment of pulmonary arterial hypertension (PAH): data from the Quality Enhancement Research Initiative [Abstract]","volume":"179","author":"McLaughlin","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.11-2212_bib32","unstructured":"Tankersley MA, D'Albini LD, Ozanich AN, Whitman AJ. A 36-month survival analysis of patients beginning oral PAH monotherapy: an indication for escalation of therapy? Poster presented at: Pulmonary Hypertension Association 8th International Pulmonary Hypertension Conference and Scientific Sessions; June 20-22, 2008; Houston, TX."}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369212606680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369212606680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T06:35:56Z","timestamp":1757918156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369212606680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0012369212606680"],"URL":"https:\/\/doi.org\/10.1378\/chest.11-2212","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717948110.793453158","asserted-by":"object"}]},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Treprostinil for the Treatment of Pulmonary Arterial Hypertension in Patients on Background Endothelin Receptor Antagonist and\/or Phosphodiesterase Type 5 Inhibitor Therapy (The FREEDOM-C Study)","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1378\/chest.11-2212","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 The American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}